Background Our aim was to investigate the role of switching from emtricitabine/tenofovir alafenamide (FTC/TAF) based regimen to a dolutegravir (DTG) containing two-drug regimen (2DR) vs continuing FTC/TAF on metabolic parameters.
OC-15 Changes in body mass index and lipid profile in PWH switching to a regimen without TAF vs PWH continuing TAF. Data from a real-life setting
Pellicano', G;
2024-01-01
Abstract
Background Our aim was to investigate the role of switching from emtricitabine/tenofovir alafenamide (FTC/TAF) based regimen to a dolutegravir (DTG) containing two-drug regimen (2DR) vs continuing FTC/TAF on metabolic parameters.File in questo prodotto:
Non ci sono file associati a questo prodotto.
Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
